Sweden’s Affibody Inks Inmagene China R&D Pact

Affibody And Inmagene Will Focus On Auto-Immune Diseases

15 May 2020

• By Sten Stovall

Swedish biotech Affibody hopes an R&D alliance with China-based Inmagene Biopharmaceuticals will speed development of its lead compound for auto-immune diseases.

China_Sweden_Coins — Duo aim to commercialize ABY-035 targeting IL-17 • Source: Shutterstock

Affibody AB of Sweden and Inmagene Biopharmaceuticals Ltd. of China have entered a strategic partnership to develop and commercialize the Swedish biotech’s lead asset, a bispecific molecule targeting Interleukin-17A for multiple auto-immune diseases that could be on the market within six years.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

01 May 2025

• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.

Novartis Gains Further Renal Territory With Regulus Acquisition

30 Apr 2025

• By Alaric DeArment

The San Diego biotech’s lead product candidate is an antisense oligonucleotide-based therapy slated to enter Phase III development in the third quarter.

GSK Chief Optimistic About BD Despite Volatile Environment

30 Apr 2025

• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: Ferrer Signs Deal For Prilenia’s Pridopidine In Europe

29 Apr 2025

• By Sushmita Panda

The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.

Scrip M&A Podcast: Will FDA Staff Cuts Impact Biopharma Dealmaking?

01 May 2025

• By Joseph Haas

Attorneys Andrew Goodman and Alan Minsk, as well as Naya CEO Daniel Teper, discussed the ramifications of US FDA staff cuts on M&A activity with Scrip senior writer Joseph Haas.